Development of a dengue exposure monitor

开发登革热暴露监测器

• 批准号: 10079069
• 负责人: JOHN E MUELLER
• 金额: $ 24.44万
• 依托单位: LYNNTECH, INC.
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-01 至 2021-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10079069
• 关键词: 4 year old; Affinity; Africa; Age; Antibodies; Asia; Biological Assay; Biological Markers; Central America; Child; Clinical Research; Communities; Contracts; Data; Dengue; Dengue Fever; Dengue Infection; Dengue Vaccine; Dengue Virus; Detection; Development; Devices; Diagnostic; Disease; Disease Outbreaks; Exposure to; FDA approved; Flavivirus; Florida; Generations; Human; Immunoglobulin G; Immunoglobulin M; Individual; Infection; Island; Life; Ligands; Medical; Monitor; Peptides; Phage Display; Phase; Plasma; Population; Protocols documentation; Risk; Safety; Sampling; Serological; Serotyping; Signal Transduction; South America; System; Testing; Texas; United States; Vaccination; Vaccines; Virus; Work; combat; electric impedance; high risk; innovation; point of care; portability; programs; user-friendly; vaccine efficacy

PROJECT SUMMARY Approximately 40% of the world’s population, 2.5 billion people, are at risk of contracting dengue fever. The disease is endemic to tropical regions in Central and South America, Africa, and Asia. Outbreaks have also occurred in the southern portions of the United States, including Florida and Texas, as well as the Hawiian islands.The FDA has approved a single vaccine against dengue. Both safety and efficacy of the vaccine depend on whether or not the recipient has been previously exposed to the dengue virus. The potential for severe dengue disease in seronegative individuals receiving the vaccination (especially for children ages 2-4) underscores the need for a field-deployable device to determine if individuals have previously been infected by the dengue virus. There is a concern that a universal vaccination program could have deleterious effects on populations living in regions where infection is the norm. Thus, a rapid, economical, point-of-care (POC) assay to determine if an individual has been exposed to the virus will be significant. Data from this assay will assist the medical community in establishing an anti-dengue vaccination protocol. Lynntech proposes to develop a portable, highly sensitive, and highly specifc diagnostic that is capable of detecting anti-dengue antibodies in human samples. Anti-dengue antibodies will be specifically recognized and captured by high affinity ligands, resulting in the generation of an electrochemical signal reflecting pre- exposure to the dengue virus. The Lynntech system will offer a straightforward, POC means to assess the serological profile of individuals with respect to their previous exposure to the dengue virus. The global need for such an assay bolsters market potential for the Lynntech product.

项目摘要 全球约有40％的人口（25亿人口）有签约粉丝的风险。这 疾病是中等和南美，非洲和亚洲的热带地区的内在。爆发也有 发生在美国南部，包括佛罗里达和德克萨斯州以及夏威夷人 Islands.FDA已批准了针对登革热的一种疫苗。疫苗的安全性和效率 取决于接受者是否以前暴露于登革热病毒。 在接收疫苗接种的血清染色个体中，严重粉丝的潜力（尤其是针对 2-4岁的儿童）强调了对野外部署设备的需求，以确定个人是否有 先前被登革热病毒感染。人们担心普遍的疫苗接种计划可以 删除了生活在感染是常态地区的人群的影响。那是一个快速，经济的 确定个体是否暴露于病毒的掌握点（POC）断言会很重要。数据 从该测定中将有助于医学界建立反登记疫苗接种方案。 lynntech提案，以开发便携式，高度敏感且高度特定的诊断，能够 检测人类样品中的抗登记抗体。将明确识别抗登记抗体 并由高亲和力配体捕获，导致产生反映前的电化学信号 暴露于登革热病毒。 Lynntech系统将提供直接的，POC的手段来评估 个体有关以前暴露于登革热病毒的血清学概况。全球需求 对于这样的测定，Bolsters的市场潜力是Lynntech产品。